United Therapeutics (NASDAQ:UTHR) Director Nilda Mesa Sells 228 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa sold 228 shares of the firm’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $505.87, for a total transaction of $115,338.36. Following the completion of the transaction, the director directly owned 5,580 shares of the company’s stock, valued at approximately $2,822,754.60. This trade represents a 3.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

United Therapeutics Trading Down 0.5%

Shares of NASDAQ:UTHR opened at $500.35 on Wednesday. United Therapeutics Corporation has a 12 month low of $397.00 and a 12 month high of $609.35. The firm’s 50-day moving average is $518.75 and its 200 day moving average is $540.72. The company has a market capitalization of $21.46 billion, a price-to-earnings ratio of 17.90, a PEG ratio of 2.52 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period last year, the business posted $6.41 EPS. As a group, equities analysts forecast that United Therapeutics Corporation will post 26.21 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Talon Private Wealth LLC increased its stake in shares of United Therapeutics by 31.8% during the 2nd quarter. Talon Private Wealth LLC now owns 6,753 shares of the biotechnology company’s stock valued at $3,659,000 after acquiring an additional 1,630 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of United Therapeutics by 4.4% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,530 shares of the biotechnology company’s stock valued at $1,371,000 after buying an additional 106 shares during the period. Tidal Investments LLC raised its stake in shares of United Therapeutics by 1.6% during the second quarter. Tidal Investments LLC now owns 34,012 shares of the biotechnology company’s stock valued at $18,429,000 after purchasing an additional 547 shares during the period. Archford Capital Strategies LLC acquired a new position in United Therapeutics in the 2nd quarter worth $552,000. Finally, Engineers Gate Manager LP acquired a new position in shares of United Therapeutics in the second quarter worth about $2,524,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on UTHR. Bank of America reduced their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a report on Thursday, August 6th. Finally, Royal Bank Of Canada lowered their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.